Company / SG&A Expense
Merck & Co. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$10.7B
FY2025
5-year range
$9.6B / $10.8B
FY2021-FY2025
Trend
-0.8%
vs FY2024
Sector context
#5 of 213
Health Care
What the data says
Among 213 Health Care companies, Merck & Co. is in the bottom 2% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $9.0B in FY2020 to $10.8B in FY2024.
Based on SEC 10-K filings.
$10.7B in FY2025 with a 5-year CAGR of +3.7%. Top quartile in the Health Care sector.
Increased from $10.5B to $10.7B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +2.2%
- 5-Year CAGR
- +3.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 213This company $10.7B Sector average $722.3M
▼
+1385.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.7%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.8% year-over-year.
- Ranks #5 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 29.6%
- Strong return on equity: 36.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.7B | -0.8% |
| FY2024 | $10.8B | +3.0% |
| FY2023 | $10.5B | +4.6% |
| FY2022 | $10.0B | +4.2% |
| FY2021 | $9.6B | +7.6% |
| FY2020 | $9.0B | -5.3% |
| FY2019 | $9.5B | -6.4% |
| FY2018 | $10.1B | +0.3% |
| FY2017 | $10.1B | +0.6% |
| FY2016 | $10.0B | -2.9% |
As of FY2025 · SEC 10-K · Updated Mar 9, 2026